FDA approves first generic of once-daily GLP-1 injection to lower blood sugar in patients with type 2 diabetes [Internet]
Clinicians are well placed to discuss the current evidence base, explain what is and is not yet available, and help you access appropriate care through legitimate channels
In early clinical trials, patients on GLP-1 agonists have achieved weight loss of 1520%, compared to the 510% typically seen with previous medications. Holistic approach to GLP-1 drugs Beyond weight loss, GLP-1 agonists have demonstrated the ability to reduce major cardiovascular events, combat fatty liver disease and alleviate obesity-related complications such as knee pain, sleep apnea, and acid reflux
Your GP surgery or pharmacist can advise on the most appropriate disposal pathway available in your area
Better cardiovascular function from weight loss improves blood flow, including blood flow to the genitals
Those two numbers, 27 and 30, form the backbone of every eligibility conversation you will ever have about GLP-1 medications
